The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non‐alcoholic fatty liver disease: 比较格列齐特、利拉鲁肽和二甲双胍对糖尿病合并非酒精性脂肪肝的影响的随机研究
Abstract
Background: The aim of the present study was to compare the effects of gliclazide, liraglutide, and metformin in type 2 diabetes mellitus (T2DM) patients with non‐alcoholic fatty liver disease (NAFLD). Methods: Eighty‐seven subjects were randomized to receive liraglutide, metformin, or gliclazide for 24 weeks. Primary outcomes included HbA1c levels, intrahepatic fat (IHF) content, and liver function. Results: Both HbA1c levels and IHF content were reduced after treatment in all three groups. However, HbA1c levels were lower in the liraglutide‐ and metformin‐treated groups than in the gliclazide‐treated group, and reductions in IHF content were greater with liraglutide than with gliclazide. Liraglutide and metformin treatments reduced weight and improved liver function. Changes in IHF content were positively correlated with reductions in serum alanine aminotransferase and triglyceride levels, as well as weight. At 24 weeks, reductions in IHF content were greater in subjects with weight loss ≥5%, changes in waistline ≤0 cm (including decreases in waistline), HbA1c reductions ≥2.5%, and HbA1c levels <6.5%. Conclusions: In T2DM patients with NAFLD, compared with liraglutide and metformin, gliclazide resulted in less improvement in liver function, reductions in IHF content and HbA1c levels, and less weight loss; in addition, slightly better improvements were achieved with liraglutide than with metformin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Tiikkainen, M., Häkkinen, A.-M., Korsheninnikova, E., Nyman, T., Mäkimattila, S., & Yki-Järvinen, H. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2169 · Cited by 524
Portillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., Subbarayan, S., Webb, A., Hecht, J., & Cusi, K. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1966 · Cited by 503
Shao, N., Kuang, H. Y., Hao, M., Gao, X. Y., Lin, W. J., & Zou, W. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2561 · Cited by 185
Torres, D. M., Jones, F. J., Shaw, J. C., Williams, C. D., Ward, J. A., & Harrison, S. A. (2011) · Hepatology · doi:10.1002/hep.24558 · Cited by 183
Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: A case series
Kenny, P. R., Brady, D. E., Torres, D. M., Ragozzino, L., Chalasani, N., & Harrison, S. A. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.363 · Cited by 106
Research works printed but not linked: 27
- 10.1002/hep.28431 · DOI · Paper page
- 10.2337/dc10-2229 · DOI · Paper page
- 10.1038/nrgastro.2013.171 · DOI · Paper page
- 10.1001/jama.2013.168118 · DOI · Paper page
- 10.6061/clinics/2015(08)06 · DOI
- 10.1007/s12328-014-0548-5 · DOI
- 10.1371/journal.pone.0076161 · DOI
- 10.1210/jc.2012-3093 · DOI · Paper page
- 10.1155/2016/4597246 · DOI
- 10.1016/j.nut.2013.11.008 · DOI
- 10.4161/15548627.2014.984271 · DOI · Paper page
- 10.1111/apt.12972 · DOI
- 10.1002/dmrr.2713 · DOI
- 10.1016/j.jdiacomp.2009.05.004 · DOI
- 10.1016/S0140-6736(15)00803-X · DOI · Paper page
- 10.2169/internalmedicine.52.8961 · DOI · Paper page
- 10.1007/s00592-014-0638-3 · DOI
- 10.1016/j.jhep.2009.04.012 · DOI · Paper page
- 10.1002/jmri.24289 · DOI
- 10.1038/oby.2011.302 · DOI
- 10.1111/apt.13521 · DOI
- 10.1002/oby.21182 · DOI
- 10.1002/dmrr.2470 · DOI
- 10.3748/wjg.v22.i10.3023 · DOI
- 10.2337/dc16-1017 · DOI
- Morita Y, 2005, Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes, Hepatogastroenterology, 52, 1338
- 10.1136/gutjnl-2015-310798 · DOI · Paper page
Cited by
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.014 · Cited by 1,211
NAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes
Godoy-Matos, A. F., Silva Júnior, W. S., & Valerio, C. M. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00570-y · Cited by 643
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., & Targher, G. (2021) · Metabolites · doi:10.3390/metabo11020073 · Cited by 299
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong, L., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H., & Guo, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1087260 · Cited by 301
Metadata
- Authors
- Feng, W., Gao, C., Bi, Y., Wu, M., Li, P., Shen, S., Chen, W., Yin, T., & Zhu, D.
- Venue
- Journal of Diabetes
- Publisher
- Wiley
- Published
- 2017-05-29
- Volume
- 9
- Issue
- 8
- Pages
- 800-809
- ISSN
- 1753-0393 (ISSN-L)
- 1753-0407
- OpenAlex
- W2598765141
- Cited by
- 164
- References
- 6
- FWCI
- 10.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- National Natural Science Foundation of China (81370947, 81570736, 81570737)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non‐alcoholic fatty liver disease: 比较格列齐特、利拉鲁肽和二甲双胍对糖尿病合并非酒精性脂肪肝的影响的随机研究. https://app.cochat.ai/papers/10.1111/1753-0407.12555
- The paper
- Feng, W., Gao, C., Bi, Y., Wu, M., Li, P., Shen, S., Chen, W., Yin, T., & Zhu, D. (2017). Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non‐alcoholic fatty liver disease: 比较格列齐特、利拉鲁肽和二甲双胍对糖尿病合并非酒精性脂肪肝的影响的随机研究. Journal of Diabetes. https://doi.org/10.1111/1753-0407.12555
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.